Effect of Neural Constraints on Movement in Stroke

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT06666673
Phase
EARLY_PHASE1
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Tizanidine — DRUG
    Tizanidine (TIZ) (Zanaflex®) is a centrally acting noradrenergic α-2 agonist and a ligand of I3 (non-I1/I2) imidazoline receptors. It is currently indicated for the management of spasticity.
  • Placebo — DRUG
    Administered as control

Study Details

This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in movement impairments may help rehabilitation efforts and assist in restoring healthy movement in individuals who have had a stroke.

Key Dates

Start date
Aug 23, 2024
Status verified
May 2026
Primary completion
Jun 30, 2029
Completion
Jul 31, 2029

Study Design

Enrollment
64 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Placebo Comparator: Placebo
    One lactose pill will be administered as a control.
  • Active Comparator: Drug Probe
    8 mg Tizanidine

Primary Outcome Measure

Brace Height [ Time Frame: Before and 1.5 hours after administration of TIZ ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Northwestern University, Dept. of PTHMS 645 N Michigan Ave, Suite 1100ChicagoIllinois60611
Julius Dewald, PhD
312-908-6788
Riegele Arceo
312-908-0847
Julius Dewald, DPT, PhD (PRINCIPAL_INVESTIGATOR)
Jun Yao, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By condition

Related Studies